Private Equity focused on Longevity & Hormone health
Delivering exceptional outcomes for doctors, patients and our investors.
About PEAL Capital
We Partner with the medical community to expand their operations
PEAL Capital is a Europe-based private equity firm focused on the longevity and hormones. We have investments in the UK, Europe, Australia and North America. We take controlling stakes in growing lower-mid-cap businesses and deliver hands-on operational and financial support from acquisition through to exit.
Years of experience
65+ years combined industry expertise
58 direct investments exits
2.33× Net MOIC
Our Mission
To improve the healthspan of the adult population aged 40-95 by working with the best doctors to roll out the most cost effective treatments that can transform people’s lives.
Our Values
We believe in disciplined execution, full alignment with management teams, and long-term, sustainable growth. We are committed to integrity, transparency and building lasting partnerships.
Reasons to Choose Us
Why Investors Choose PEAL Capital
As the only private equity firm dedicated exclusively to the longevity and hormones sector, PEAL is deploying a three-fund strategy that spans the entire supply chain, securing proprietary off-market opportunities and giving investors full-spectrum exposure.
Proprietary deal flow via trusted networks
Due diligence focused on historical and live data - not projections!
Hands-on value creation throughout the organisation
Targeted exit strategies with staged holding periods
Strong alignment with management and their consumers
Track record of consistent, risk-adjusted returns
Investement Track Record
Successful Exits
Deal Size Range
Net MOIC/IRR
Meet Our Team
A Trusted Team With Decades of Investment and Operational Experience
Want to join our growing team?
Karen O'Mahony
Founder & Managing Partner
Brendan McDonagh
Chair
Tara Mandal
Partner & COO PEAL Capital Group
Lynda Hayden
Head of Operations PEAL Capital Group
News
News and Insights From the PEAL Capital Group
FDA Announcement: A pivotal time for the health of women
10 November 2025 marks a momentous time in history for women. The Food and Drug Administration (FDA) commissioner Dr Marty Makary has announced in a public meeting that the warnings for estrogen products in hormone replacement therapy (HRT) and vaginal hormones are...
DermaHub Launch
On 1st November 2023, Derma Medical launched the world’s first e-learning hub for Aesthetics professionals. DermaHub will be the first of its kind to offer a subscription-based platform that will allow delegates to access the highest-quality online training from...
TAIC Meet-Up
Karen O'Mahony attends The Alternative Investment Club's Meet-Up, LONGEVITY: Not Only Living Longer but Better PEAL's Managing Partner, Karen O'Mahony, thoroughly enjoyed sharing her insights on Longevity alongside the panel at The Alternative Investment Club's...
PEAL Capital Partners Swiss AG is a registered member of Finanzombudsstelle Schweiz (FINOS)
Registered Office: Weidstrasse 9b
6300 Zug, Switzerland
Navigation
Our Approach
Newsletter
Copyright © 2025 PEAL CAPITAL GROUP All rights reserved.